Base de dados : MEDLINE
Pesquisa : D04.210.500.365.415.638 [Categoria DeCS]
Referências encontradas : 2267 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 227 ir para página                         

  1 / 2267 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29232412
[Au] Autor:Selakovic D; Joksimovic J; Zaletel I; Puskas N; Matovic M; Rosic G
[Ad] Endereço:Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
[Ti] Título:The opposite effects of nandrolone decanoate and exercise on anxiety levels in rats may involve alterations in hippocampal parvalbumin-positive interneurons.
[So] Source:PLoS One;12(12):e0189595, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to evaluate the behavioral effects of chronic (six weeks) nandrolone decanoate (ND, 20 mg/kg, s.c., weekly in single dose) administration (in order to mimic heavy human abuse), and exercise (swimming protocol of 60 minutes a day, five days in a row/two days break), applied alone and simultaneously with ND, in male rats (n = 40). Also, we evaluated the effects of those protocols on hippocampal parvalbumin (PV) content and the possible connection between the alterations in certain parts of hippocampal GABAergic system and behavioral patterns. Both ND and exercise protocols induced increase in testosterone, dihydrotestosterone and estradiol blood levels. Our results confirmed anxiogenic effects of ND observed in open field (OF) test (decrease in the locomotor activity, as well as in frequency and cumulative duration in the centre zone) and in elevated plus maze (EPM) test (decrease in frequency and cumulative duration in open arms, and total exploratory activity), that were accompanied with a mild decrease in the number of PV interneurons in hippocampus. Chronic exercise protocol induced significant increase in hippocampal PV neurons (dentate gyrus and CA1 region), followed by anxiolytic-like behavioral changes, observed in both OF and EPM (increase in all estimated parameters), and in evoked beam-walking test (increase in time to cross the beam), compared to ND treated animals. The applied dose of ND was sufficient to attenuate beneficial effects of exercise in rats by means of decreased exercise-induced anxiolytic effect, as well as to reverse exercise-induced augmentation in number of PV immunoreactive neurons in hippocampus. Our results implicate the possibility that alterations in hippocampal PV interneurons (i.e. GABAergic system) may be involved in modulation of anxiety level induced by ND abuse and/or extended exercise protocols.
[Mh] Termos MeSH primário: Hipocampo/efeitos dos fármacos
Interneurônios/metabolismo
Nandrolona/análogos & derivados
Parvalbuminas/metabolismo
Condicionamento Físico Animal
[Mh] Termos MeSH secundário: Animais
Comportamento Animal/efeitos dos fármacos
Hipocampo/metabolismo
Hipocampo/fisiopatologia
Masculino
Nandrolona/farmacologia
Ratos
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Parvalbumins); 6PG9VR430D (Nandrolone); H45187T098 (nandrolone decanoate)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189595


  2 / 2267 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Volpon, José Batista
Texto completo SciELO Brasil
[PMID]:29236797
[Au] Autor:Guimarães APFGM; Butezloff MM; Zamarioli A; Issa JPM; Volpon JB
[Ad] Endereço:Fellow Master degree, Postgraduate Program in Health Sciences Applied to the Locomotor System, School of Medicine, Universidade de São Paulo (USP), Ribeirao Preto-SP, Brazil. Design of the study, technical procedures, acquisition and interpretation of data, manuscript preparation.
[Ti] Título:Nandrolone decanoate appears to increase bone callus formation in young adult rats after a complete femoral fracture.
[So] Source:Acta Cir Bras;32(11):924-934, 2017 Nov.
[Is] ISSN:1678-2674
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To evaluate the influence of nandrolone decanoate on fracture healing and bone quality in normal rats. METHODS: Male rats were assigned to four groups (n=28/group): Control group consisting of animals without any intervention, Nandrolone decanoate (DN) group consisting of animals that received intramuscular injection of nandrolone decanoate, Fracture group consisting of animals with a fracture at the mid-diaphysis of the femur, and Fracture and nandrolone decanoate group consisting of animals with a femur fracture and treatment with nandrolone decanoate. Fractures were created at the mid-diaphysis of the right femur by a blunt trauma and internally fixed using an intramedullary steel wire. The DN was injected intramuscularly twice per week (10 mg/kg of body mass). The femurs were measured and evaluated by densitometry and mechanical resistance after animal euthanasia. The newly formed bone and collagen type I levels were quantified in the callus. RESULTS: The treated animals had longer femurs after 28 days. The quality of the intact bone was not significantly different between groups. The bone callus did show a larger mass in the treated rats. CONCLUSION: The administration of nandrolone decanoate did not affect the quality of the intact bone, but might have enhanced the bone callus formation.
[Mh] Termos MeSH primário: Anabolizantes/farmacologia
Calo Ósseo/fisiologia
Fraturas do Fêmur/tratamento farmacológico
Consolidação da Fratura/efeitos dos fármacos
Nandrolona/análogos & derivados
[Mh] Termos MeSH secundário: Animais
Densidade Óssea/fisiologia
Consolidação da Fratura/fisiologia
Masculino
Nandrolona/farmacologia
Ratos
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anabolic Agents); 6PG9VR430D (Nandrolone); H45187T098 (nandrolone decanoate)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE


  3 / 2267 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29097219
[Au] Autor:Tofighi A; Ahmadi S; Seyyedi SM; Shirpoor A; Kheradmand F; Gharalari FH
[Ad] Endereço:Department of Exercise Physiology, Faculty of Physical Education and Sport Sciences, Urmia University, Urmia, Iran.
[Ti] Título:Nandrolone administration with or without strenuous exercise promotes overexpression of nephrin and podocin genes and induces structural and functional alterations in the kidneys of rats.
[So] Source:Toxicol Lett;282:147-153, 2018 Jan 05.
[Is] ISSN:1879-3169
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Among the various adverse effects of nandrolone administration with or without strenuous exercise, kidney abnormalities, where there are associations between nandrolone decanoate consumption, have not been well defined yet. The aim of this study was to investigate the effect of nandrolone decanoate intake with or without strenuous exercise on nephrin and podocin gene expressions, cystatin C, oxidative DNA damage, and histological changes in the kidneys of rats. Thirty-two male wistar rats were assigned into four groups, namely control, nandrolone, nandrolone with strenuous exercise, and strenuous exercise groups. After six weeks of treatment, the results revealed a significant increase in the nephrin and podocin gene expression, plasma cystatin C, and the amount of 8-OHdG in the kidney tissue; as well as a decrease in creatinine clearance in nandrolone and nandrolone with strenuous exercise groups compared to the control group. Moreover, compared to the control group, the nandrolone and the nandrolone with strenuous exercise groups, showed histological changes such as fibrosis and kidney tissue cells proliferation. These findings indicate that nandrolone induces kidney abnormalities, which may in part be associated with overexpression of nephrin and podocin genes mediated by oxidative stress, which was manifested in increased 8-OHdG in kidney tissue.
[Mh] Termos MeSH primário: Anabolizantes/toxicidade
Peptídeos e Proteínas de Sinalização Intracelular/genética
Rim/efeitos dos fármacos
Proteínas de Membrana/genética
Nandrolona/toxicidade
Condicionamento Físico Animal
[Mh] Termos MeSH secundário: Animais
Cistatina C/sangue
Desoxiguanosina/análogos & derivados
Desoxiguanosina/metabolismo
Expressão Gênica/efeitos dos fármacos
Rim/metabolismo
Rim/patologia
Masculino
Estresse Oxidativo/efeitos dos fármacos
Ratos Wistar
Natação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anabolic Agents); 0 (Cystatin C); 0 (Intracellular Signaling Peptides and Proteins); 0 (Membrane Proteins); 0 (NPHS2 protein); 0 (nephrin); 6PG9VR430D (Nandrolone); 88847-89-6 (8-oxo-7-hydrodeoxyguanosine); G9481N71RO (Deoxyguanosine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171201
[Lr] Data última revisão:
171201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171104
[St] Status:MEDLINE


  4 / 2267 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28911934
[Au] Autor:Osuga Y; Fujimoto-Okabe H; Hagino A
[Ad] Endereço:Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan. Electronic address: yutakaos-tky@umin.ac.jp.
[Ti] Título:Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study.
[So] Source:Fertil Steril;108(4):673-678, 2017 Oct.
[Is] ISSN:1556-5653
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the efficacy and safety of dienogest (DNG), a progestational 19-norsteroid, in patients with symptomatic adenomyosis. DESIGN: Phase III, randomized, double-blind, multicenter, placebo-controlled study. SETTING: Clinical study sites in Japan. PATIENT(S): Sixty-seven patients with adenomyosis. INTERVENTION(S): Patients were randomly assigned to receive DNG (2 mg/d, orally) or placebo for 16 weeks. In cases of complicated anemia, patients were treated for anemia before randomization. MAIN OUTCOME MEASURE(S): The primary end point was the change from baseline to after treatment pain score, using zero- to three-point verbal rating scales that defined pain severity according to limited ability to work and need for analgesics. The visual analogue scale was used as another pain parameter. RESULT(S): Decreases from baseline in the pain score and the visual analogue scale at the end of treatment were significantly more in the DNG group than in the placebo group (P<.001). During the treatment period, almost all of the patients treated with DNG experienced irregular uterine bleeding and one patient had mild anemia. No severe cases of anemia were observed. CONCLUSION(S): These results suggest that DNG is effective and well tolerated in the treatment for painful symptoms associated with adenomyosis not complicated by severe uterine enlargement or severe anemia. CLINICAL TRIAL REGISTRATION NUMBER: JapicCTI-142642(en).
[Mh] Termos MeSH primário: Adenomiose/tratamento farmacológico
Nandrolona/análogos & derivados
Dor Pélvica/tratamento farmacológico
[Mh] Termos MeSH secundário: Adenomiose/complicações
Adulto
Método Duplo-Cego
Feminino
Seres Humanos
Japão
Distúrbios Menstruais/complicações
Distúrbios Menstruais/tratamento farmacológico
Meia-Idade
Nandrolona/uso terapêutico
Medição da Dor
Dor Pélvica/etiologia
Placebos
Índice de Gravidade de Doença
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Placebos); 46M3EV8HHE (dienogest); 6PG9VR430D (Nandrolone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170916
[St] Status:MEDLINE


  5 / 2267 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28582442
[Au] Autor:Joksimovic J; Selakovic D; Matovic M; Zaletel I; Puskas N; Rosic G
[Ad] Endereço:Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
[Ti] Título:The role of neuropeptide-Y in nandrolone decanoate-induced attenuation of antidepressant effect of exercise.
[So] Source:PLoS One;12(6):e0178922, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Since the increased prevalence of anabolic androgenic steroids abuse in last few decades is usually accompanied by various exercise protocols, the scope of our study was to evaluate the effects of chronic nandrolone decanoate administration in supraphysiological dose and a prolonged swimming protocol (alone and simultaneously with nandrolone decanoate) on depressive state in male rats. Simultaneously, we investigated the possible alterations in neuropeptide Y (NPY) content in blood and the hippocampus, in order to determine the role of NPY in the modulation of depressive-like behavior.Exercise induced antidepressant effects in tail suspension test (decrease of the total duration of immobility), as well as significant increase in the number of hippocampal NPY-interneurons in CA1 region. Chronic nandrolone decanoate treatment attenuated the beneficial antidepressant effects of exercise as measured by the tail suspension test parameters. Simultaneously, nandrolone decanoate treatment resulted in diminution of NPY content both in blood (decreased serum levels) and in hippocampus (the significant decrease in NPY expression in all three investigated hippocampal regions-CA1, CA2/3 and DG). Our findings indicate that alterations in serum and hippocampal NPY contents may underlie the changes in depressive state in rats. The exercise was beneficial as it exerted antidepressant effect, while chronic nandrolone decanoate treatment resulted in depressive-like behavior. Furthermore, the behavioral indicators of depression showed strong correlations with the serum levels and the hippocampal content of NPY.
[Mh] Termos MeSH primário: Anabolizantes/efeitos adversos
Depressão/metabolismo
Expressão Gênica/efeitos dos fármacos
Nandrolona/análogos & derivados
Neuropeptídeo Y/metabolismo
Condicionamento Físico Animal
[Mh] Termos MeSH secundário: Animais
Comportamento Animal/efeitos dos fármacos
Região CA1 Hipocampal/efeitos dos fármacos
Região CA1 Hipocampal/metabolismo
Região CA2 Hipocampal/efeitos dos fármacos
Região CA2 Hipocampal/metabolismo
Região CA3 Hipocampal/efeitos dos fármacos
Região CA3 Hipocampal/metabolismo
Giro Denteado/efeitos dos fármacos
Giro Denteado/metabolismo
Depressão/genética
Depressão/fisiopatologia
Imobilização
Interneurônios/efeitos dos fármacos
Interneurônios/metabolismo
Masculino
Nandrolona/efeitos adversos
Neuropeptídeo Y/antagonistas & inibidores
Neuropeptídeo Y/genética
Ratos
Ratos Wistar
Natação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anabolic Agents); 0 (Neuropeptide Y); 6PG9VR430D (Nandrolone); H45187T098 (nandrolone decanoate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170606
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0178922


  6 / 2267 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28412309
[Au] Autor:Buoso E; Galasso M; Ronfani M; Papale A; Galbiati V; Eberini I; Marinovich M; Racchi M; Corsini E
[Ad] Endereço:Dipartimento di Scienze del Farmaco, Università degli Studi di Pavia, Viale Taramelli 12/14, 27100 Pavia, Italy.
[Ti] Título:The scaffold protein RACK1 is a target of endocrine disrupting chemicals (EDCs) with important implication in immunity.
[So] Source:Toxicol Appl Pharmacol;325:37-47, 2017 Jun 15.
[Is] ISSN:1096-0333
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We recently demonstrated the existence of a complex hormonal balance between steroid hormones in the control of RACK1 (Receptor for Activated C Kinase 1) expression and immune activation, suggesting that this scaffold protein may also be targeted by endocrine disrupting chemicals (EDCs). As a proof of concept, we investigated the effect of the doping agent nandrolone, an androgen receptor (AR) agonist, and of p,p'DDT (dichlorodiphenyltrichloroethane) and its main metabolite p,p'DDE (dichlorodiphenyldichloroethylene), a weak and strong AR antagonist, respectively, on RACK1 expression and innate immune response. In analogy to endogenous androgens, nandrolone induced a dose-related increase in RACK1 transcriptional activity and protein expression, resulting in increased LPS-induced IL-8 and TNF-α production and proliferation in THP-1 cells. Conversely, p,p'DDT and p,p'DDE significantly decrease RACK1 expression, LPS-induced cytokine production and CD86 expression; with p,p'DDE exerting a stronger repressor effect than p,p'DDT, consistent with its stronger AR antagonistic effect. These results indicate that RACK1 could be a relevant target of EDCs, responding in opposite ways to agonist or antagonist of AR, representing a bridge between the endocrine system and the innate immune system.
[Mh] Termos MeSH primário: Disruptores Endócrinos/toxicidade
Proteínas de Ligação ao GTP/metabolismo
Imunidade Inata/efeitos dos fármacos
Linfócitos/efeitos dos fármacos
Proteínas de Neoplasias/metabolismo
Receptores de Superfície Celular/metabolismo
[Mh] Termos MeSH secundário: Antagonistas de Androgênios/toxicidade
Androgênios/toxicidade
Antígeno B7-2/metabolismo
Linhagem Celular
Proliferação Celular/efeitos dos fármacos
DDT/toxicidade
Diclorodifenil Dicloroetileno/toxicidade
Proteínas de Ligação ao GTP/genética
Seres Humanos
Interleucina-8/metabolismo
Lipopolissacarídeos/farmacologia
Ativação Linfocitária/efeitos dos fármacos
Linfócitos/enzimologia
Linfócitos/imunologia
Nandrolona/toxicidade
Proteínas de Neoplasias/genética
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Receptores de Quinase C Ativada
Receptores Androgênicos/efeitos dos fármacos
Receptores Androgênicos/metabolismo
Receptores de Superfície Celular/genética
Receptores de Glucocorticoides/efeitos dos fármacos
Receptores de Glucocorticoides/metabolismo
Transdução de Sinais/efeitos dos fármacos
Transcrição Genética/efeitos dos fármacos
Transfecção
Fator de Necrose Tumoral alfa/metabolismo
Regulação para Cima
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (AR protein, human); 0 (Androgen Antagonists); 0 (Androgens); 0 (B7-2 Antigen); 0 (CD86 protein, human); 0 (Endocrine Disruptors); 0 (IL8 protein, human); 0 (Interleukin-8); 0 (Lipopolysaccharides); 0 (Neoplasm Proteins); 0 (RACK1 protein, human); 0 (RNA, Messenger); 0 (Receptors for Activated C Kinase); 0 (Receptors, Androgen); 0 (Receptors, Cell Surface); 0 (Receptors, Glucocorticoid); 0 (Tumor Necrosis Factor-alpha); 4M7FS82U08 (Dichlorodiphenyl Dichloroethylene); 6PG9VR430D (Nandrolone); CIW5S16655 (DDT); EC 3.6.1.- (GTP-Binding Proteins)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170417
[St] Status:MEDLINE


  7 / 2267 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28234904
[Au] Autor:Siddiqui M; Ahmad MS; Wahab AT; Yousuf S; Fatima N; Naveed Shaikh N; Rahman AU; Choudhary MI
[Ad] Endereço:H. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
[Ti] Título:Biotransformation of a potent anabolic steroid, mibolerone, with Cunninghamella blakesleeana, C. echinulata, and Macrophomina phaseolina, and biological activity evaluation of its metabolites.
[So] Source:PLoS One;12(2):e0171476, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Seven metabolites were obtained from the microbial transformation of anabolic-androgenic steroid mibolerone (1) with Cunninghamella blakesleeana, C. echinulata, and Macrophomina phaseolina. Their structures were determined as 10ß,17ß-dihydroxy-7α,17α-dimethylestr-4-en-3-one (2), 6ß,17ß-dihydroxy-7α,17α-dimethylestr-4-en-3-one (3), 6ß,10ß,17ß-trihydroxy-7α,17α-dimethylestr-4-en-3-one (4), 11ß,17ß-dihydroxy-(20-hydroxymethyl)-7α,17α-dimethylestr-4-en-3-one (5), 1α,17ß-dihydroxy-7α,17α-dimethylestr-4-en-3-one (6), 1α,11ß,17ß-trihydroxy-7α,17α-dimethylestr-4-en-3-one (7), and 11ß,17ß-dihydroxy-7α,17α-dimethylestr-4-en-3-one (8), on the basis of spectroscopic studies. All metabolites, except 8, were identified as new compounds. This study indicates that C. blakesleeana, and C. echinulata are able to catalyze hydroxylation at allylic positions, while M. phaseolina can catalyze hydroxylation of CH2 and CH3 groups of substrate 1. Mibolerone (1) was found to be a moderate inhibitor of ß-glucuronidase enzyme (IC50 = 42.98 ± 1.24 µM) during random biological screening, while its metabolites 2-4, and 8 were found to be inactive. Mibolerone (1) was also found to be significantly active against Leishmania major promastigotes (IC50 = 29.64 ± 0.88 µM). Its transformed products 3 (IC50 = 79.09 ± 0.06 µM), and 8 (IC50 = 70.09 ± 0.05 µM) showed a weak leishmanicidal activity, while 2 and 4 were found to be inactive. In addition, substrate 1 (IC50 = 35.7 ± 4.46 µM), and its metabolite 8 (IC50 = 34.16 ± 5.3 µM) exhibited potent cytotoxicity against HeLa cancer cell line (human cervical carcinoma). Metabolite 2 (IC50 = 46.5 ± 5.4 µM) also showed a significant cytotoxicity, while 3 (IC50 = 107.8 ± 4.0 µM) and 4 (IC50 = 152.5 ± 2.15 µM) showed weak cytotoxicity against HeLa cancer cell line. Compound 1 (IC50 = 46.3 ± 11.7 µM), and its transformed products 2 (IC50 = 43.3 ± 7.7 µM), 3 (IC50 = 65.6 ± 2.5 µM), and 4 (IC50 = 89.4 ± 2.7 µM) were also found to be moderately toxic to 3T3 cell line (mouse fibroblast). Interestingly, metabolite 8 showed no cytotoxicity against 3T3 cell line. Compounds 1-4, and 8 were also evaluated for inhibition of tyrosinase, carbonic anhydrase, and α-glucosidase enzymes, and all were found to be inactive.
[Mh] Termos MeSH primário: 17-Cetosteroides/metabolismo
Antineoplásicos/metabolismo
Antiprotozoários/metabolismo
Cunninghamella/metabolismo
Nandrolona/análogos & derivados
Saccharomycetales/metabolismo
Congêneres da Testosterona/metabolismo
[Mh] Termos MeSH secundário: 17-Cetosteroides/química
17-Cetosteroides/isolamento & purificação
17-Cetosteroides/farmacologia
Animais
Antineoplásicos/química
Antineoplásicos/isolamento & purificação
Antineoplásicos/farmacologia
Antiprotozoários/química
Antiprotozoários/isolamento & purificação
Antiprotozoários/farmacologia
Biotransformação
Anidrases Carbônicas/química
Sobrevivência Celular/efeitos dos fármacos
Cromatografia Líquida de Alta Pressão
Cunninghamella/química
Cunninghamella/efeitos dos fármacos
Glucuronidase/antagonistas & inibidores
Glucuronidase/química
Células HeLa
Seres Humanos
Hidroxilação
Leishmania major/efeitos dos fármacos
Leishmania major/crescimento & desenvolvimento
Camundongos
Estrutura Molecular
Monofenol Mono-Oxigenase/química
Células NIH 3T3
Nandrolona/química
Nandrolona/metabolismo
Nandrolona/farmacologia
Saccharomycetales/química
Saccharomycetales/efeitos dos fármacos
Congêneres da Testosterona/química
Congêneres da Testosterona/isolamento & purificação
Congêneres da Testosterona/farmacologia
alfa-Glucosidases/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (17-Ketosteroids); 0 (Antineoplastic Agents); 0 (Antiprotozoal Agents); 0 (Testosterone Congeners); 6PG9VR430D (Nandrolone); 9OGY4BOR8D (mibolerone); EC 1.14.18.1 (Monophenol Monooxygenase); EC 3.2.1.20 (alpha-Glucosidases); EC 3.2.1.31 (Glucuronidase); EC 4.2.1.1 (Carbonic Anhydrases)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170225
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0171476


  8 / 2267 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28231497
[Au] Autor:Leonardo-Pinto JP; Benetti-Pinto CL; Cursino K; Yela DA
[Ad] Endereço:Department of Gynecology and Obstetrics, School of Medical Sciences, University of Campinas, (UNICAMP), Campinas, SP, Brazil.
[Ti] Título:Dienogest and deep infiltrating endometriosis: The remission of symptoms is not related to endometriosis nodule remission.
[So] Source:Eur J Obstet Gynecol Reprod Biol;211:108-111, 2017 Apr.
[Is] ISSN:1872-7654
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the effectiveness of dienogest in controlling pain caused by deep infiltrating endometriosis (DIE), its influence on the quality of live (QoL) of women affected by the disease, and the effect of the drug on the volume of endometriotic lesions. STUDY DESIGN: A prospective cohort study including 30 women with a sonographic diagnosis of DIE (intestinal and posterior fornix) treated with dienogest 2mg per day for 12 months. We evaluated the pain symptoms and the volume of the intestinal and posterior fornix lesions before and after 12 months of use of dienogest. To perform the statistical analysis, we used the Wilcoxon signed-rank test, and the relationship between the data was tested using the Spearman correlation coefficient. RESULTS: Women were on average 36.13±6.24years old. Pain symptoms most commonly reported were dyspareunia (83.3%), dysmenorrhea (73.3%), and pelvic pain (66.7%). After 12 months of treatment with dienogest, there was significant improvement of various symptoms (dyspareunia p=0.0093, dysmenorrhea p<0.0001; pelvic pain p=0.0007; and bowel pain p<0.0001), without a reduction in the volume of endometriotic nodules. There were significant improvements in the parameters that comprise the QoL (physical p<0.0001; p=0.0007 psychological) and the self-assessment of QoL (p=0.0069) and health (p=0.0001). CONCLUSION: Dienogest is an effective medication to control symptoms of pain related to DIE, even without reducing the volume of DIE nodules.
[Mh] Termos MeSH primário: Endometriose/tratamento farmacológico
Antagonistas de Hormônios/uso terapêutico
Enteropatias/tratamento farmacológico
Nandrolona/análogos & derivados
Dor Pélvica/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Constipação Intestinal/tratamento farmacológico
Constipação Intestinal/etiologia
Constipação Intestinal/patologia
Endometriose/complicações
Endometriose/patologia
Feminino
Seres Humanos
Enteropatias/complicações
Enteropatias/patologia
Nandrolona/uso terapêutico
Medição da Dor
Dor Pélvica/etiologia
Dor Pélvica/patologia
Estudos Prospectivos
Qualidade de Vida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hormone Antagonists); 46M3EV8HHE (dienogest); 6PG9VR430D (Nandrolone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170224
[St] Status:MEDLINE


  9 / 2267 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28192127
[Au] Autor:Caliman IF; Bernabe CS; de Melo AF; Brasil GA; do Nascimento AM; de Lima EM; Figueiredo SG; de Andrade TU; Bissoli NS
[Ad] Endereço:Department of Physiological Sciences, Federal University of Espirito Santo, Vitória, Espirito Santo, Brazil. Electronic address: icaliman12@gmail.com.
[Ti] Título:Long-term treatment with Nandrolone Decanoate impairs mesenteric vascular relaxation in both sedentary and exercised female rats.
[So] Source:Steroids;120:7-18, 2017 Apr.
[Is] ISSN:1878-5867
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Nandrolone Decanoate (ND) is an Anabolic Androgenic Steroid (AAS) that under abusive regimen can lead to multiple physiological adverse effects. Studies of AAS-mediated cardiovascular (CV) alterations were mostly taken from male subjects, even though women are also susceptible to the effects of AAS and gender-specific differences in susceptibility to vascular diseases exist. Here we investigate ND-induced vascular reactivity alterations in both sedentary and exercised female rats and whether these alterations depend on endothelium-derived factors. We show that chronic exposure of female Wistar rats to ND (20mg/Kg/week for 4weeks) impaired the vascular mesenteric bed (MVB) reactivity to vasodilator (acetylcholine) agonist. The endothelium-dependent Nitric Oxide (NO) component was reduced in ND-treated rats, whereas neither the endothelium-derived hyperpolarizing factor (EDHF) component nor prostanoids were altered in the MVBs. Endothelial dysfunction observed in ND-treated rats was associated with decreased eNOS (Ser ) and Akt (Ser ) phosphorylation sites and upregulation of iNOS and NADPH oxidase expression. Exercise training by weight lifting in water did not improve the vascular alterations induced by ND treatment. ND treatment also significantly reduced the serum levels of estradiol in females, overriding its CV protective effect. These results help uncover the role of ND modulating endothelial function in the setting of CV disease caused by the abuse of AAS in females. If this translates to humans, young women abusing AAS can potentially lose the cardio protective effect rendered by estrogen and be more susceptible to CV alterations.
[Mh] Termos MeSH primário: Anabolizantes/farmacologia
Nandrolona/análogos & derivados
Condicionamento Físico Animal/fisiologia
[Mh] Termos MeSH secundário: Adiposidade/efeitos dos fármacos
Animais
Fatores Biológicos/metabolismo
Ingestão de Alimentos/efeitos dos fármacos
Feminino
Artérias Mesentéricas/efeitos dos fármacos
Modelos Biológicos
NADPH Oxidases/metabolismo
Nandrolona/farmacologia
Óxido Nítrico/metabolismo
Óxido Nítrico Sintase Tipo II/metabolismo
Prostaglandinas/metabolismo
Ratos
Ratos Wistar
Vasodilatação/efeitos dos fármacos
Ganho de Peso/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anabolic Agents); 0 (Biological Factors); 0 (Prostaglandins); 0 (endothelium-dependent hyperpolarization factor); 31C4KY9ESH (Nitric Oxide); 6PG9VR430D (Nandrolone); EC 1.14.13.39 (Nitric Oxide Synthase Type II); EC 1.6.3.- (NADPH Oxidases); H45187T098 (nandrolone decanoate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170214
[St] Status:MEDLINE


  10 / 2267 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28189702
[Au] Autor:Ebert AD; Dong L; Merz M; Kirsch B; Francuski M; Böttcher B; Roman H; Suvitie P; Hlavackova O; Gude K; Seitz C
[Ad] Endereço:Praxis for Women's Health, Gynecology & Obstetrics, Berlin, Germany. Electronic address: info@prof-ebert.de.
[Ti] Título:Dienogest 2 mg Daily in the Treatment of Adolescents with Clinically Suspected Endometriosis: The VISanne Study to Assess Safety in ADOlescents.
[So] Source:J Pediatr Adolesc Gynecol;30(5):560-567, 2017 Oct.
[Is] ISSN:1873-4332
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:STUDY OBJECTIVE: To study the safety and efficacy of dienogest 2 mg in adolescents with suspected endometriosis. DESIGN: A 52-week, open-label, single-arm study. SETTING: In 21 study centers, in 6 European countries. PARTICIPANTS: Adolescents aged 12 to younger than 18 years with clinically suspected or laparoscopically confirmed endometriosis. INTERVENTIONS: Dienogest 2 mg once daily. MAIN OUTCOME MEASURES: The primary end point was relative change in lumbar spine (L2-L4) bone mineral density (BMD) measured using dual-energy x-ray absorptiometry. A key secondary end point was change in endometriosis-associated pain assessed using a visual analogue scale. RESULTS: Of 120 patients screened, 111 comprised the full-analysis set (ie, patients who took ≥1 dose of study drug and had ≥1 post-treatment observation) and 97 (87.4%) completed the study. Mean lumbar BMD at baseline was 1.1046 (SD, 0.1550) g/cm . At the end of dienogest treatment (EOT; defined as at 52 weeks or premature study discontinuation), mean relative change in BMD from baseline was -1.2% (SD, 2.3%; n = 103). Follow-up measurement 6 months after EOT in the subgroup with decreased BMD at EOT (n = 60) showed partial recovery in lumbar BMD (mean change from baseline: -2.3% at EOT, -0.6% 6 months after EOT). Mean endometriosis-associated pain score was 64.3 (SD, 19.1) mm at baseline and decreased to 9.0 (SD, 13.9) mm by week 48. CONCLUSION: In adolescents with suspected endometriosis, dienogest 2 mg for 52 weeks was associated with a decrease in lumbar BMD, followed by partial recovery after treatment discontinuation. Endometriosis-associated pain was substantially reduced during treatment. Because bone accretion is critical during adolescence, results of the VISanne study to assess safety in ADOlescents (VISADO) study highlights the need for tailored treatment in this population, taking into account the expected efficacy on endometriosis-associated pain and an individual's risk factors for osteoporosis.
[Mh] Termos MeSH primário: Densidade Óssea/efeitos dos fármacos
Endometriose/tratamento farmacológico
Antagonistas de Hormônios/uso terapêutico
Nandrolona/análogos & derivados
[Mh] Termos MeSH secundário: Absorciometria de Fóton
Adolescente
Criança
Europa (Continente)
Feminino
Antagonistas de Hormônios/efeitos adversos
Seres Humanos
Vértebras Lombares
Nandrolona/efeitos adversos
Nandrolona/uso terapêutico
Medição da Dor
Dor Pélvica/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Hormone Antagonists); 46M3EV8HHE (dienogest); 6PG9VR430D (Nandrolone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170213
[St] Status:MEDLINE



página 1 de 227 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde